Videos

The neurologist at the University of Oklahoma Medical Center highlighted early diagnosis, prevention of secondary injury, and multimodal monitoring as key to improving patient outcomes in TBI. [WATCH TIME: 5 minutes]

At AAN 2026, an associate professor of neurology at University of Washington discussed how delays in antiamyloid treatment initiation for early Alzheimer disease may be driven by real-world factors. [WATCH TIME: 5 minutes]

A medical student at at Santa Casa de São Paulo School of Medical Sciences discussed the findings from a systematic review suggest potential biomarker-level benefits of estradiol-based hormone therapy in Alzheimer disease, but cautions that heterogeneous data limit firm conclusions. [WATCH TIME: 3 minutes]

Coordinated Duchenne care transitions align cardiology, pulmonary and neuromuscular handoffs, protecting families from risky gaps after 18.

Clinicians tailor Duchenne steroid therapy over time—balancing benefits, side effects, and family capacity for monitoring newer treatments like gene therapy and givinostat.

See how care coordinators sync cardiology, pulmonology and neuromuscular visits so Duchenne teens move to adult care without gaps.

Clinicians weigh vamorolone vs prednisone/deflazacort, tailoring growth and weight goals while managing tricky steroid switches and adrenal risks.

In the final episode, 'Multidisciplinary Approaches to Long-Term Narcolepsy Care,' the panelists explore the multidisciplinary challenges inherent in managing narcolepsy over the long term, opening with a candid discussion of how fragmented healthcare systems and limited communication infrastructure make true care coordination difficult. In practice, the burden of bridging different care teams often falls on the patient, with the expert panel encouraging patients to keep all providers informed of treatment changes to avoid conflicting approaches.

The associate professor of neurology at Mayo Clinic Rochester discussed why earlier detection of environmental risk in Parkinson disease remains difficult and how gene-environment research may help move the field forward. [WATCH TIME: 4 minutes]

Neurology News Network for the week ending April 18, 2026. [WATCH TIME: 5 minutes]

The senior global medical director at Sanofi discussed the ongoing burden of CIDP, highlighting diagnostic challenges, treatment gaps, and the need for improved biomarkers and emerging therapies. [WATCH TIME: 3 minutes]

This episode, titled 'Optimizing Narcolepsy Treatment Through Polypharmacy,' features panelists discussing the role of polypharmacy in narcolepsy treatment, challenging the notion that a single agent is sufficient for most patients. While research suggests roughly 60% of narcolepsy patients are on multiple medications, the expert panel notes that in their own clinical practices the rate is considerably higher, reflecting a more aggressive pursuit of optimal outcomes. The anticipated arrival of orexin receptor agonists is acknowledged as potentially transformative, though the expert panel stops short of assuming any single agent will address the full spectrum of narcolepsy symptoms.

Clinicians weigh vamorolone vs prednisone/deflazacort for young boys, balancing growth, weight, and adrenal safety during steroid transitions.

Duchenne care now reaches adulthood—discover when to plan transition, boost teen independence, and find adult clinics that support lifelong needs.

Explore today’s Duchenne muscular dystrophy treatment options, from corticosteroids and givinostat to gene therapy and exon skipping, plus evolving dosing debates.

Clinicians weigh safety, dosing, and combo therapies in Duchenne, balancing infusion burden, ethics, and gene-transfer risks before decline.

In 'Assessing DEA Scheduling and Emerging Therapies in Narcolepsy,' our panel delves into the practical implications of DEA scheduling on narcolepsy treatment decisions, noting that available medications span the scheduling spectrum from unscheduled agents like pitolisant to schedule three oxybates and schedule two stimulants.

The medical director of neurointerventional surgery at Allina Health Brain and Spine Institute provided clinical insights on the procedural factors that guide patient selection for endovascular stroke intervention. [WATCH TIME: 3 minutes]

The senior vice president of clinical development for Lundbeck discusses the mechanism and early clinical promise of Lu AF28996, an oral dual D1/D2 agonist for advanced Parkinson disease. [WATCH TIME: 3 minutes]

Raj Rajaraman, MD, MS, discussed the broad treatment landscape for CDD, highlighting current therapies, neuromodulation, surgical options, and emerging gene-targeted strategies.

Raj Rajaraman, MD, MS, discussed the variable seizure patterns, treatment challenges, and EEG monitoring considerations in patients with CDKL5 deficiency disorder.

Neurology News Network for the week ending April 11, 2026. [WATCH TIME: 4 minutes]

The director of neuromuscular medicine at Marcus Neuroscience Institute shared findings from an analysis presented at MDA 2026 that compared real-world infection rates associated with generalized myasthenia gravis therapies. [WATCH TIME: 8 minutes]

The director of Neuromuscular Medicine at Children’s Hospital of The King’s Daughters discussed the phase 4 RESPOND trial and how add-on nusinersen may improve motor function and biomarker outcomes in patients with spinal muscular atrophy following gene therapy.

The director of the Neurology Residency Program at the Marcus Neuroscience Institute talked about the role of research, patient empowerment, and expanding treatment options in multiple sclerosis. [WATCH TIME: 5 minutes]

In this discussion, Dr Brenda Wong explores how families can be supported by advocacy organizations after a Duchenne muscular dystrophy diagnosis. She elaborates on how care needs evolve across the lifespan, and how advocacy organizations can help guide multidisciplinary care, treatment decisions, care transitions, and participation in cutting edge DMD research.

Explore today’s DMD treatment toolkit—from steroids and givinostat to gene therapy and exon skipping—plus dosing debates shaping care.

A teen with Duchenne shows how exon-skipping and steroids shape care, while clinicians stress realistic expectations amid varied progression.

In this episode, 'Narcolepsy Treatment Considerations in Pediatric Patients', the experts explore the pharmacologic treatment of narcolepsy in pediatric patients, beginning with a review of FDA-approved options for children. The expert panel notes that the oxybate class, including sodium oxybate, low-sodium oxybate, and once-nightly oxybate, carries approval for excessive daytime sleepiness and cataplexy in patients seven and older, while pitolisant is approved for ages six and up for both indications, including a recently added cataplexy indication. The expert panel clarifies that traditional stimulants and solriamfetol have not been specifically studied or approved for cataplexy treatment.

The chief research officer of the Muscular Dystrophy Association spoke on the FDA's approval of a high-dose regimen of nusinersen and how it fits into an increasingly complex treatment landscape. [WATCH TIME: 11 minutes]